Xencor develops patent portfolios for various XmAb® cytokine and bispecific antibodies and uses thereof
Client(s) Xencor, Inc.
Jones Day represents Xencor, Inc. in developing global patent portfolios related to various XmAb® cytokine and bispecific antibody clinical candidates and uses thereof for the treatment of cancer and other disorders.